文献速递肝病

遗传风险对前瞻性评估的2型糖尿病患者晚期纤维化和肝硬化患病率的影响

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.
PubMed 文献 · Aliment Pharmacol Ther · 2024-06-02

研究前瞻性纳入382例≥50岁2型糖尿病患者,以PNPLA3、TM6SF2、SERPINA1风险等位基因减去HSD17B13保护变异计算多基因风险评分,用磁共振弹性成像和振动控制瞬时弹性成像评估晚期纤维化和肝硬化,发现高评分与肝硬化风险升高相关,将评分纳入美国胃肠病学会和美国肝病研究学会筛查指南可减少约20%晚期纤维化患者被错误归为低风险。

要点

  • 晚期纤维化和肝硬化患病率分别为12.3%和5.2%。
  • 高多基因风险评分与肝硬化风险升高相关(2.7% vs 7.5%,p=0.037)。
  • FIB-4<1.3者中高评分与晚期纤维化风险升高相关(9.6% vs 2.3%,p=0.036)。

核心结论

  • 在表型明确的前瞻性2型糖尿病成人队列中,将遗传风险评估加入高危人群筛查推荐可能改善风险预测。

研究设计与样本

  • 前瞻性队列研究,从门诊招募≥50岁2型糖尿病成人共382例。
  • 多基因风险评分为PNPLA3、TM6SF2和SERPINA1风险等位基因之和减去HSD17B13保护变异。
  • 采用磁共振弹性成像和振动控制瞬时弹性成像评估晚期纤维化和肝硬化。

主要发现

  • 382例患者平均年龄64.8(±8.4)岁,平均BMI 31.7(±6.2)kg/m2。
  • 晚期纤维化患病率12.3%,肝硬化患病率5.2%。
  • 较高的多基因风险评分与肝硬化风险升高相关(2.7% vs 7.5%,p=0.037)。
  • 在FIB-4指数<1.3者中,高多基因风险评分与晚期纤维化风险升高相关(9.6% vs 2.3%,p=0.036),其他FIB-4类别中无显著差异。
  • 将多基因风险评分纳入美国胃肠病学会和美国肝病研究学会筛查指南,防止约20%的晚期纤维化参与者被不适当地归类为低风险。

关键数值与推荐

  • 高多基因风险评分与肝硬化风险升高相关(2.7% vs 7.5%,p=0.037)。
  • FIB-4<1.3者中高多基因风险评分与晚期纤维化风险升高相关(9.6% vs 2.3%,p=0.036)。
  • 将多基因风险评分纳入美国胃肠病学会和美国肝病研究学会筛查指南可防止约20%的晚期纤维化参与者被不适当地归类为低风险。

临床怎么用

  • 作者认为,将遗传风险评估加入高危人群筛查推荐可能改善风险预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic factors contribute to the risk and severity of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the utility of genetic testing in risk stratification remains poorly characterised. AIMS: To examine the influence of genetic risk on advanced fibrosis and cirrhosis in patients with type 2 diabetes mellitus (T2DM) and the utility of a polygenic risk score (PRS) in screening guidelines. METHODS: We prospectively enrolled adults aged ≥50 years with T2DM recruited from clinics. PRS was the sum of risk alleles in PNPLA3, TM6SF2 and SERPINA1 minus the protective variant in HSD17B13. We performed magnetic resonance elastography and vibration-controlled transient elastography to assess for advanced fibrosis and cirrhosis. RESULTS: Of 382 included patients, the mean age and BMI were 64.8 (±8.4) years and 31.7 (±6.2) kg/m2 respectively. The prevalence of advanced fibrosis and cirrhosis were 12.3% and 5.2% respectively; higher PRS was associated with increased risk of cirrhosis (2.7% vs. 7.5%, p = 0.037). High PRS was associated with increased risk of advanced fibrosis among those with fibrosis-4 index (FIB-4) index <1.3 (9.6% vs. 2.3%, p = 0.036) but was not significantly different in other FIB-4 categories. Incorporating PRS determination into the American Gastroenterological Association and American Association for the Study of Liver Diseases screening guidelines prevented approximately 20% of all participants with advanced fibrosis from being inappropriately classified as low risk. CONCLUSIONS: Utilising a well-phenotyped, prospective cohort of adults with T2DM, we found that adding an assessment of genetic risk to recommendations to screen at-risk populations may improve risk prediction.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bridi L, Agrawal S, Tesfai K, et al. The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes. Aliment Pharmacol Ther. 2024. PMID: 38825972. doi:10.1111/apt.18099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。